In the published article, there was an error in Figure 3 as published. The wrong slide of microscopy was provided for OVX + E group in Figure 3A. There were incorrect kDa values of Vglut2 and Vgat due to clerical errors, and there were red curves below kDa and Vgat caused by spell checking in Figures 3H, K. The corrected Figure 3 and its caption appear below.
Figure 3
In the published article, there was an error in Figure 6 as published. There were red curves below kDa caused by spell checking in Figures 6F, I. The corrected Figure 6 and its caption appear below.
Figure 6
In the published article, there was an error in Figure 9 as published. There were red curves below kDa and Vgat caused by spell checking in Figures 9D, G, and the abbreviation for ERα antagonist, AZD, was misspelled as ZAD due to an error in Figures 9E, H. And there were incorrect kDa values in the caption due to clerical errors. The corrected Figure 9 and its caption appear below.
Figure 9
In the published article, there was an error in Figure 10 as published. There were red curves below kDa and Vgat caused by spell checking in Figures 10D, G, and the abbreviation for ERβ antagonist, PHT, was misspelled as AZD or ZAD due to an error in Figures 10D, G. And there were incorrect kDa values in the caption due to clerical errors. The corrected Figure 10 and its caption appear below.
Figure 10
In the published article, there were errors in the text. The abbreviation for ERα antagonist, AZD, was misspelled as ZAD due to a clerical error.
In the section, Results, ERα regulated Vglut2 and vgat as a transcription factor, Paragraph 2. This sentence previously stated:
“After injection of ERα agonist into POA of OVX group, the expression of mRNA and protein of Vglut2 increased significantly (90.36 ± 4.69 vs 43.4 ± 3.87, p < 0.001; 73.92 ± 4.85 vs 40.20 ± 3.46, p < 0.001; respectively), which was significantly higher than that in SHAM + AZD (p < 0.05) and OVX + E + ZAD (p < 0.05) groups, while there was no significant difference between SHAM + AZD and OVX + E + ZAD groups (Figures 9C–E).”
The corrected sentence appears below:
“After injection of ERα agonist into POA of OVX group, the expression of mRNA and protein of Vglut2 increased significantly (90.36 ± 4.69 vs. 43.4 ± 3.87, p < 0.001; 73.92 ± 4.85 vs. 40.20 ± 3.46, p < 0.001; respectively), which was significantly higher than that in SHAM + AZD (p < 0.05) and OVX + E + AZD (p < 0.05) groups, while there was no significant difference between SHAM + AZD and OVX + E + AZD groups (Figures 9C–E).”
In Results, ERα regulated Vglut2 and vgat as a transcription factor, Paragraph 3, the sentence previously stated:
“After injection of ERα agonist into POA of OVX group, the expression of mRNA and protein of Vgat decreased significantly (131.56 ± 8.14 vs 179.2 ± 7.94, p < 0.001; 66.36 ± 4.62 vs 87.72 ± 5.15, p < 0.001; respectively), and there was no significant difference between SHAM + AZD, OVX + PPT and OVX + E + ZAD groups (Figures 9F–H).”
The corrected sentence appears below:
“After injection of ERα agonist into POA of OVX group, the expression of mRNA and protein of Vgat decreased significantly (131.56 ± 8.14 vs. 179.2 ± 7.94, p < 0.001; 66.36 ± 4.62 vs. 87.72 ± 5.15, p < 0.001; respectively), and there was no significant difference between SHAM + AZD, OVX + PPT and OVX + E + AZD groups (Figures 9F–H).”
In Results, ERβ regulated Vglut2 and Vgat as a transcription factor, Paragraph 2, the sentence previously stated:
“After injection of ERβ agonist into POA of OVX group, the expression of mRNA and protein of Vglut2 increased significantly (65.26 ± 6.25 vs. 54.61 ± 6.92, p < 0.01; 71.25 ± 4.85 vs, 52.64 ± 4.36, p < 0.01, respectively), which was significantly higher than that in SHAM + AZD (mRNA: p < 0.05; protein: p < 0.01) and OVX + E + ZAD (mRNA: p < 0.05; protein: p < 0.01) groups, while there was no significant difference between SHAM + AZD and OVX + E + ZAD groups (Figures 10C–E).”
The corrected sentence appears below:
“After injection of ERβ agonist into POA of OVX group, the expression of mRNA and protein of Vglut2 increased significantly (65.26 ± 6.25 vs. 54.61 ± 6.92, p < 0.01; 71.25 ± 4.85 vs, 52.64 ± 4.36, p < 0.01, respectively), which was significantly higher than that in SHAM + PHT (mRNA: p < 0.05; protein: p < 0.01) and OVX + E + PHT (mRNA: p < 0.05; protein: p < 0.01) groups, while there was no significant difference between SHAM + PHT and OVX + E + PHT groups (Figures 10C–E).”
In Results, ERβ regulated Vglut2 and Vgat as a transcription factor, Paragraph 3, the sentence previously stated:
“After injection of ERβ agonist into POA of OVX group, the expression of mRNA and protein of Vgat decreased significantly (146.56 ± 8.14 vs. 168.26 ± 7.94, p < 0.05; 72.86 ± 5.81 vs. 93.5 ± 5.21, p < 0.01, respectively), which was still significantly higher than that in SHAM + AZD (mRNA: p < 0.01; protein: p < 0.05) and OVX + E + ZAD (mRNA: p < 0.01; protein: p < 0.05) groups, while there was no significant difference between SHAM + AZD and OVX + E + ZAD groups (Figures 10F–H).”
The corrected sentence appears below:
“After injection of ERβ agonist into POA of OVX group, the expression of mRNA and protein of Vgat decreased significantly (146.56 ± 8.14 vs. 168.26 ± 7.94, p < 0.05; 72.86 ± 5.81 vs. 93.5 ± 5.21, p < 0.01, respectively), which was still significantly higher than that in SHAM + PHT (mRNA: p < 0.01; protein: p < 0.05) and OVX + E + PHT (mRNA: p < 0.01; protein: p < 0.05) groups, while there was no significant difference between SHAM + PHT and OVX + E + PHT groups (Figures 10F–H).”
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
hot flashes, glutamatergic neurons, GABAergic neurons, glutamate decarboxylase, thermosensitive transient receptor potentials, estrogen receptors
Citation
Sun Y, Wang H, Wang W, Lu J, Zhang J, Luo X, Luan L, Wang K, Jia J, Yan J and Qin L (2024) Corrigendum: Glutamatergic and GABAergic neurons in the preoptic area of the hypothalamus play key roles in menopausal hot flashes. Front. Aging Neurosci. 16:1072608. doi: 10.3389/fnagi.2024.1072608
Received
17 October 2022
Accepted
17 June 2024
Published
04 July 2024
Volume
16 - 2024
Edited and reviewed by
Jorge Busciglio, University of California, Irvine, United States
Updates
Copyright
© 2024 Sun, Wang, Wang, Lu, Zhang, Luo, Luan, Wang, Jia, Yan and Qin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lihua Qin qinlihua88@bjmu.edu.cnJunhao Yan yjh@bjmu.edu.cnJing Jia jiajing1996@aliyun.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.